Literature DB >> 21904567

Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy.

Arjun Balar1, Dean F Bajorin, Matthew I Milowsky.   

Abstract

Bladder cancer is a common malignancy seen in older adults with coexisting medical illnesses. The management of patients with muscle invasive disease includes perioperative chemotherapy and radical cystectomy; however, patients may decline surgery and older patients with comorbid conditions may not be candidates for surgery and thus alternative treatment strategies are needed. Trimodality bladder preservation protocols for muscle invasive bladder cancer have generally included only those patients who are candidates for a salvage cystectomy. In this review, we discuss the current status of bladder preservation treatment options for patients with muscle-invasive disease who are not candidates for cystectomy or who decline surgery and highlight the need for clinical trials investigating novel treatment approaches in this older patient population.

Entities:  

Keywords:  TURBT; bladder cancer; bladder preservation; cystectomy; octogenarians; radiation therapy; transitional cell carcinoma; transurethral resection of bladder tumor; urothelial carcinoma

Year:  2011        PMID: 21904567      PMCID: PMC3159398          DOI: 10.1177/1756287211407543

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN: 1756-2872


  57 in total

Review 1.  Biologic and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin.

Authors:  C T Coughlin; R C Richmond
Journal:  Semin Oncol       Date:  1989-08       Impact factor: 4.929

2.  Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.

Authors:  H Varveris; D Delakas; P Anezinis; D Haldeopoulos; M Mazonakis; J Damilakis; G Metaxaris; N Chondros; E Mavromanolakis; G Daskalopoulos; A Dimitrakopoulos; A Kranidis
Journal:  Anticancer Res       Date:  1997 Nov-Dec       Impact factor: 2.480

3.  The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.

Authors:  D S Kaufman; K A Winter; W U Shipley; N M Heney; M P Chetner; L Souhami; R A Zlotecki; W T Sause; L D True
Journal:  Oncologist       Date:  2000

4.  Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience.

Authors:  Wassim Kassouf; David Swanson; Ashish M Kamat; Dan Leibovici; Arlene Siefker-Radtke; Mark F Munsell; H Barton Grossman; Colin P N Dinney
Journal:  J Urol       Date:  2006-06       Impact factor: 7.450

5.  Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.

Authors:  Donatella Tirindelli Danesi; Giorgio Arcangeli; Enrico Cruciani; Pierluigi Altavista; Antonella Mecozzi; Bianca Saracino; Filina Orefici
Journal:  Cancer       Date:  2004-12-01       Impact factor: 6.860

Review 6.  Organ-sparing strategies in the management of invasive bladder cancer.

Authors:  Faysal A Yafi; Fabio L Cury; Wassim Kassouf
Journal:  Expert Rev Anticancer Ther       Date:  2009-12       Impact factor: 4.512

7.  Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy.

Authors:  Joseph M Herman; David C Smith; James Montie; James A Hayman; Molly A Sullivan; Elizabeth Kent; Kent A Griffith; Peggy Esper; Howard M Sandler
Journal:  Urology       Date:  2004-07       Impact factor: 2.649

8.  Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer.

Authors:  W U Shipley; D S Kaufman; E Zehr; N M Heney; S C Lane; H K Thakral; A F Althausen; A L Zietman
Journal:  Urology       Date:  2002-07       Impact factor: 2.649

9.  Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.

Authors:  Claus Rödel; Gerhard G Grabenbauer; Reinhard Kühn; Thomas Papadopoulos; Jürgen Dunst; Martin Meyer; Karl M Schrott; Rolf Sauer
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544

10.  Organ preservation for muscle-invasive bladder cancer by transurethral resection.

Authors:  Dan Leibovici; Wassim Kassouf; Louis L Pisters; Curtis A Pettaway; Xifeng Wu; Colin P Dinney; H Barton Grossman
Journal:  Urology       Date:  2007-09       Impact factor: 2.649

View more
  9 in total

Review 1.  Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder.

Authors:  Kirk A Keegan; Matthew J Resnick; Peter E Clark
Journal:  Curr Opin Oncol       Date:  2012-05       Impact factor: 3.645

2.  Clinical outcomes of patients with pure small cell carcinoma of the urinary bladder.

Authors:  Gokmen Umut Erdem; Mutlu Dogan; Aydin Aytekin; Suleyman Sahin; Havva Yeşil Cinkir; Abdullah Sakin; Melike Ozcelik; Oktay Bozkurt; Emel Sezer; Nebi Serkan Demirci; Yakup Bozkaya; Nurullah Zengin
Journal:  Ir J Med Sci       Date:  2019-08-28       Impact factor: 1.568

3.  Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).

Authors:  Patricia Moretto; Lori Wood; Urban Emmenegger; Normand Blais; Som Dave Mukherjee; Eric Winquist; Eric Charles Belanger; Robert Macrae; Alexander Balogh; Ilias Cagiannos; Wassim Kassouf; Peter Black; Piotr Czaykowski; Joel Gingerich; Scott North; Scott Ernst; Suzanne Richter; Srikala Sridhar; M Neil Reaume; Denis Soulieres; Andrea Eisen; Christina M Canil
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

4.  Phase II study of everolimus in metastatic urothelial cancer.

Authors:  Matthew I Milowsky; Gopa Iyer; Ashley M Regazzi; Hikmat Al-Ahmadie; Scott R Gerst; Irina Ostrovnaya; Lan L Gellert; Rana Kaplan; Ilana R Garcia-Grossman; Deepa Pendse; Arjun V Balar; Anne Marie Flaherty; Alisa Trout; David B Solit; Dean F Bajorin
Journal:  BJU Int       Date:  2013-04-03       Impact factor: 5.588

5.  Transurethral resection and degeneration of bladder tumour.

Authors:  Aihua Li; Wei Fang; Feng Zhang; Weiwu Li; Honghai Lu; Sikuan Liu; Hui Wang; Binghui Zhang
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

6.  Urothelial carcinoma management in elderly or unfit patients.

Authors:  Joaquim Bellmunt; Nicolas Mottet; Maria De Santis
Journal:  EJC Suppl       Date:  2016-03-22

7.  Bladder Preservation with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for the Treatment of Muscle-invasive Carcinoma of the Bladder: A Single-Center Experience.

Authors:  Chinmayee Agrawal; Saurabh Bansal; Manoj Biswas; Meenu Gupta; Vipul Nautiyal; Mushtaq Ahmed
Journal:  South Asian J Cancer       Date:  2021-04-26

8.  Radical cystectomy in frail octogenarians in thoracic continuous spinal anesthesia and analgesia: a pilot study.

Authors:  Daniele Castellani; Roberto Starnari; Lucia Faloia; Massimo Stronati; Alfredo Venezia; Luca Gasparri; Redi Claudini; Alessandro Branchi; Marina Giampieri; Marco Dellabella
Journal:  Ther Adv Urol       Date:  2018-09-03

9.  Synergistic effect between cisplatin and sunitinib malate on human urinary bladder-cancer cell lines.

Authors:  Regina Arantes-Rodrigues; Rosário Pinto-Leite; Lio Fidalgo-Gonçalves; Carlos Palmeira; Lúcio Santos; Aura Colaço; Paula Oliveira
Journal:  Biomed Res Int       Date:  2013-11-28       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.